ArticleFrontiers in aging neuroscience2023
Lipoprotein(a) and stroke: a two-sample Mendelian randomization study.
Article in Frontiers in aging neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Mendelian randomization studies on ischemic stroke: a field synopsis and systematic review.Journal of translational medicine · 2025Pooled it
- The Lipoprotein(a) Implementation Gap: Bridging Evidence and Clinical Practice.Reviews in cardiovascular medicine · 2026Review
- Ancestral Variation in Lp(a): Epidemiology, Isoform Diversity, and Testing.Current atherosclerosis reports · 2025Review
- Demographics of lipoprotein(a) and stroke: The UK biobank.American journal of preventive cardiology · 2025Article
- Lipoprotein(a) as a Stroke Biomarker: Pathophysiological Pathways and Therapeutic Implications.Journal of clinical medicine · 2025Review
- Serum EpCAM or PECAM Levels and Risk of Ischemic Stroke: A Two-Sample Mendelian Randomization Study.Molecular neurobiology · 2025Article
- Lipoprotein(a) as a Causal Risk Factor for Cardiovascular Disease.Current cardiovascular risk reports · 2025Review
- Lipoprotein (a) and cerebrovascular disease.The Journal of international medical research · 2024Review
- Lipoprotein(a) and the Risk for Recurrent Ischemic Stroke Events.JACC. Advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate the causal relationship between lipoprotein(a) Lp(a) and stroke risk. Method: Adopting two grand scale genome-wide association study (GWAS) databases, the instrumental variables were selected on the basis that the genetic loci met the criteria of being independent of each other and closely related to Lp(a). Summary-level data for outcomes, ischemic stroke and its subtypes were acquired from the UK Biobank and MEGASTROKE consortium databases. Two-sample MR analyses were achieved using inverse variance-weighted (IVW) meta-analysis (primary analysis), weighted median analysis, and the MR Egger regression method. Multivariable-adjusted Cox regression models were also used for observational analysis. Result: Genetically predicted Lp(a) was marginally related with higher odds of total stroke (odds ratio (OR) [95% confidence intervals (CI)]: 1.003 [1.001-1.006], Conclusion: Genetically predicted higher Lp(a) perhaps rise the risk of total stroke, ischemic stroke, and large-artery atherosclerotic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.